Klaus Schollmeier
Direktor/Vorstandsmitglied bei CUREVAC N.V.
Vermögen: 11 624 $ am 30.04.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Thomas Meier | M | 62 | 20 Jahre | |
Anne-Marie Lund Winther | M | - |
Pcovery ApS
Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | 14 Jahre |
John Bondo Hansen | M | - |
Pcovery ApS
Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | - |
Peter Sondermann | M | 60 |
TACALYX GmbH
TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany. | - |
Marco J. Janezic | M | - |
Eternygen GmbH
Eternygen GmbH Pharmaceuticals: MajorHealth Technology Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany. | 12 Jahre |
Casper Hansen | M | - |
Pcovery ApS
Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | 11 Jahre |
Emmanuelle Coutanceau | M | 44 |
Inthera Bioscience AG
Inthera Bioscience AG BiotechnologyHealth Technology Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland.
Pcovery ApS
Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | - |
Francois Spertini | M | - |
Anergis SA
Anergis SA Pharmaceuticals: GenericHealth Technology Anergis SA develops allergy vaccines. It is a biopharmaceutical company specializing in the discovery and development of novel, proprietary allergy vaccines that target commercially attractive indications and the firm’s vaccines are based on its IP-protected Contiguous Overlapping Peptide technology.The company was founded by Francois Spertini in August 2001 and is headquartered in Epalinges, Switzerland. | 23 Jahre |
Ulrike Gnad-Vogt | M | - | 13 Jahre | |
Sarah Fakih | M | - | - | |
Peter H. Seeberger | M | - |
TACALYX GmbH
TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany. | - |
Oliver Strub | M | 61 | 18 Jahre | |
William Dalby-Brown | M | - |
Pcovery ApS
Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | - |
Michael Brosnan | M | 69 | 1 Jahre | |
Debra Stephanie Barker | M | 61 | 2 Jahre | |
Vanya Beltrami | M | - |
Anergis SA
Anergis SA Pharmaceuticals: GenericHealth Technology Anergis SA develops allergy vaccines. It is a biopharmaceutical company specializing in the discovery and development of novel, proprietary allergy vaccines that target commercially attractive indications and the firm’s vaccines are based on its IP-protected Contiguous Overlapping Peptide technology.The company was founded by Francois Spertini in August 2001 and is headquartered in Epalinges, Switzerland. | 10 Jahre |
Detlev Mennerich | M | 55 |
TACALYX GmbH
TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany. | - |
Bettina Jödicke-Braas | F | - | - | |
Alexander Kettner | M | - |
Anergis SA
Anergis SA Pharmaceuticals: GenericHealth Technology Anergis SA develops allergy vaccines. It is a biopharmaceutical company specializing in the discovery and development of novel, proprietary allergy vaccines that target commercially attractive indications and the firm’s vaccines are based on its IP-protected Contiguous Overlapping Peptide technology.The company was founded by Francois Spertini in August 2001 and is headquartered in Epalinges, Switzerland. | - |
Frank Odds | M | - |
Pcovery ApS
Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | - |
Grit Zahn | M | - |
Eternygen GmbH
Eternygen GmbH Pharmaceuticals: MajorHealth Technology Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany. | 11 Jahre |
Peter Finan | M | 57 |
Eternygen GmbH
Eternygen GmbH Pharmaceuticals: MajorHealth Technology Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany. | - |
Patrick Baumhof | M | - | - | |
Hans-Jochem Kolb | M | - |
Minaris Regenerative Medicine GmbH
Minaris Regenerative Medicine GmbH BiotechnologyHealth Technology apceth Biopharma GmbH operates as a contract development & manufacturing organization. The firm specializes in cell-based and gene therapy products (Advanced Therapy Medicinal Products, ATMPs). Its GMP services include quality management, quality control, assay development, process development, cell banking & formulation and project management. The company was founded in 2007 and is headquartered in Munich, Germany. | - |
Gerard Farmer | M | - |
Anergis SA
Anergis SA Pharmaceuticals: GenericHealth Technology Anergis SA develops allergy vaccines. It is a biopharmaceutical company specializing in the discovery and development of novel, proprietary allergy vaccines that target commercially attractive indications and the firm’s vaccines are based on its IP-protected Contiguous Overlapping Peptide technology.The company was founded by Francois Spertini in August 2001 and is headquartered in Epalinges, Switzerland. | 13 Jahre |
Malte Greune | M | 59 | 3 Jahre | |
Antony Blanc | M | 57 | 4 Jahre | |
Viola Bronsema | M | 61 | 4 Jahre | |
Lena Krzyzak | M | - |
TACALYX GmbH
TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany. | - |
Alexander Ehlgen | M | - |
TACALYX GmbH
TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany. | 4 Jahre |
Sebastian Puenzeler | M | - |
TACALYX GmbH
TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany. | - |
Keno Gutierrez | M | - |
Inthera Bioscience AG
Inthera Bioscience AG BiotechnologyHealth Technology Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland. | - |
Anker Gunvald Lundemose | M | 63 |
Inthera Bioscience AG
Inthera Bioscience AG BiotechnologyHealth Technology Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland. | - |
Mathias Hothum | M | 58 | 9 Jahre | |
Roland Walder | M | - |
Inthera Bioscience AG
Inthera Bioscience AG BiotechnologyHealth Technology Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland. | - |
Craig Tooman | M | 58 | 5 Jahre | |
Markus Hosang | M | - |
Anergis SA
Anergis SA Pharmaceuticals: GenericHealth Technology Anergis SA develops allergy vaccines. It is a biopharmaceutical company specializing in the discovery and development of novel, proprietary allergy vaccines that target commercially attractive indications and the firm’s vaccines are based on its IP-protected Contiguous Overlapping Peptide technology.The company was founded by Francois Spertini in August 2001 and is headquartered in Epalinges, Switzerland. | - |
Manfred Rüdiger | M | 59 |
Minaris Regenerative Medicine GmbH
Minaris Regenerative Medicine GmbH BiotechnologyHealth Technology apceth Biopharma GmbH operates as a contract development & manufacturing organization. The firm specializes in cell-based and gene therapy products (Advanced Therapy Medicinal Products, ATMPs). Its GMP services include quality management, quality control, assay development, process development, cell banking & formulation and project management. The company was founded in 2007 and is headquartered in Munich, Germany. | - |
Cord Dohrmann | M | 60 |
Eternygen GmbH
Eternygen GmbH Pharmaceuticals: MajorHealth Technology Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany. | - |
Zoltán Czigler | M | - |
Anergis SA
Anergis SA Pharmaceuticals: GenericHealth Technology Anergis SA develops allergy vaccines. It is a biopharmaceutical company specializing in the discovery and development of novel, proprietary allergy vaccines that target commercially attractive indications and the firm’s vaccines are based on its IP-protected Contiguous Overlapping Peptide technology.The company was founded by Francois Spertini in August 2001 and is headquartered in Epalinges, Switzerland. | 13 Jahre |
Sten Verland | M | 67 |
Anergis SA
Anergis SA Pharmaceuticals: GenericHealth Technology Anergis SA develops allergy vaccines. It is a biopharmaceutical company specializing in the discovery and development of novel, proprietary allergy vaccines that target commercially attractive indications and the firm’s vaccines are based on its IP-protected Contiguous Overlapping Peptide technology.The company was founded by Francois Spertini in August 2001 and is headquartered in Epalinges, Switzerland. | - |
Baron Jean Stéphenne | M | 73 | 9 Jahre | |
Mark R.L. Krul | M | - |
Inthera Bioscience AG
Inthera Bioscience AG BiotechnologyHealth Technology Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland. | - |
Karlheinz Schmelig | M | - |
TACALYX GmbH
TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany. | - |
Alexander Zehnder | M | 54 | 1 Jahre | |
Ulrich Mahr | M | - |
TACALYX GmbH
TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany. | - |
Peter Neubeck | M | - |
TACALYX GmbH
TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany. | - |
Matthias Kromayer | M | 58 |
Minaris Regenerative Medicine GmbH
Minaris Regenerative Medicine GmbH BiotechnologyHealth Technology apceth Biopharma GmbH operates as a contract development & manufacturing organization. The firm specializes in cell-based and gene therapy products (Advanced Therapy Medicinal Products, ATMPs). Its GMP services include quality management, quality control, assay development, process development, cell banking & formulation and project management. The company was founded in 2007 and is headquartered in Munich, Germany. | - |
Pierre Kemula | M | 50 | 8 Jahre | |
Ilka Wicke | M | - |
Pcovery ApS
Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | - |
Martin N. Bonde | M | 61 |
Inthera Bioscience AG
Inthera Bioscience AG BiotechnologyHealth Technology Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland. | 4 Jahre |
Vincent Charlon | M | - |
Anergis SA
Anergis SA Pharmaceuticals: GenericHealth Technology Anergis SA develops allergy vaccines. It is a biopharmaceutical company specializing in the discovery and development of novel, proprietary allergy vaccines that target commercially attractive indications and the firm’s vaccines are based on its IP-protected Contiguous Overlapping Peptide technology.The company was founded by Francois Spertini in August 2001 and is headquartered in Epalinges, Switzerland. | 15 Jahre |
Michael Broberg Palmgren | M | - |
Pcovery ApS
Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | 15 Jahre |
Poul Nissen | M | - |
Pcovery ApS
Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | 15 Jahre |
Myriam Mendila | M | 58 | 1 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Barbara Anna Heller | F | 56 | 7 Jahre | |
Martin Gertsch | M | 59 | 15 Jahre | |
Rudolf Hausmann | M | - | - | |
Michael Fisher | M | - |
BASF Bioresearch Corp.
| 3 Jahre |
Igor Splawski | M | 56 | 3 Jahre | |
Klaus Edvardsen | M | 62 | 1 Jahre | |
Nicholas Coppard | M | 65 | 9 Jahre | |
Ralf Clemens | M | 71 | 8 Jahre | |
Andreas Mielimonka | M | 70 |
Heinrich-Heine-Universität Düsseldorf
| 4 Jahre |
Hildegard Müller | F | 56 |
Heinrich-Heine-Universität Düsseldorf
| 5 Jahre |
Mario Hermann Daberkow | M | 54 |
Heinrich-Heine-Universität Düsseldorf
| 5 Jahre |
Franz-Werner Haas | M | 54 | 11 Jahre | |
Hans Tanner | M | 72 | 8 Jahre | |
Kimi Iguchi | F | 61 | 3 Jahre | |
Robert Kamen | M | 79 |
BASF Bioresearch Corp.
| 10 Jahre |
Peter J. Licari | M | 60 |
BASF Bioresearch Corp.
| 3 Jahre |
Peter Wolf | M | - | - | |
Helmut H. Kessmann | M | 64 | 7 Jahre | |
Jürg Ambühl | M | 75 | - | |
Georg Nebgen | M | 62 | - | |
Mark C. Clement | M | - | 6 Jahre | |
Hans-Peter Hasler | M | 68 | 5 Jahre | |
Michael Lytton | M | 67 | 7 Jahre | |
David L. Berstein | M | 72 |
BASF Bioresearch Corp.
| 3 Jahre |
Bernd Seizinger | M | 67 | 7 Jahre | |
Timothy James Rink | M | 78 | 9 Jahre | |
Rudolf Gygax | M | - | 5 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Deutschland | 39 | 47,56% |
Schweiz | 31 | 37,80% |
Dänemark | 9 | 10,98% |
Vereinigte Staaten | 4 | 4,88% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Klaus Schollmeier
- Persönliches Netzwerk